Ateganosine (THIO-101)

July 8, 2026: MAIA Biotechnology, Inc. (NYSE: MAIA) reported positive initial efficacy data from Part C (expansion) of its Phase 2 THIO-101 trial evaluating ateganosine followed by cemiplimab (Libtayo) as third-line (3L) therapy in advanced non-small cell lung cancer (NSCLC). As of July 6, 2026, the interim efficacy-evaluable population (patients with at least one post-treatment tumor scan) showed a 90.5% disease control rate (DCR; 19/21). The company noted these observations are consistent with prior THIO-101 Parts A and B results, including a previously reported 88% DCR in 3L NSCLC, despite Part C enrolling a more heavily pre-treated population (all previously received docetaxel and had resistance to both immunotherapy and other chemotherapies).

MAIA also stated it has completed international enrollment in Part C and that ateganosine followed by cemiplimab has shown an acceptable safety profile to date. THIO-101 is a multicenter, open-label, dose-finding Phase 2 trial with overall response rate (ORR) as the primary efficacy endpoint (ClinicalTrials.gov: NCT05208944).